Related Experiment Video

Updated: Dec 10, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.2K

[Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis]

Brenda Zylbersztajn1, Giannina Izquierdo C1, Daniel Navea M1

  • 1Clínica Las Condes, Chile.

Revista Chilena De Infectologia : Organo Oficial De La Sociedad Chilena De Infectologia
|August 28, 2020
PubMed

Insights

Optimal dosing of piperacillin tazobactam (PT) is crucial for pediatric patients on extracorporeal membrane oxygenation (ECMO). This study found that current PT dosing often fails to achieve therapeutic piperacillin concentrations in these critically ill children.

Area of Science:

  • Pediatric Critical Care Medicine
  • Pharmacology
  • Extracorporeal Life Support

Background:

  • Optimal dosing of piperacillin tazobactam (PT) is not well-established in pediatric patients requiring extracorporeal membrane oxygenation (ECMO).
  • Understanding drug pharmacokinetics in ECMO patients is essential for effective treatment.

Purpose of the Study:

  • To determine piperacillin plasma concentrations in pediatric patients receiving PT during ECMO.
  • To assess the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets with PT in this population.

Main Methods:

  • A case series involving three pediatric patients on ECMO treated with PT.
  • Piperacillin plasma levels were measured using high-performance liquid chromatography (HPLC) mid-dose interval.

Main Results:

  • Piperacillin plasma concentrations varied significantly among patients (51.7, 14.1, and 6.5 μg/mL).
  • Only one of the three patients achieved adequate therapeutic piperacillin concentrations.

Conclusions:

  • Preliminary findings suggest that piperacillin dosing may need adjustment in pediatric ECMO patients.
  • Monitoring plasma concentrations could help optimize PT therapy and improve PK/PD target attainment in this vulnerable group.
Abstract

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.6K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
172
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
125
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
147